|
1
|
American Cancer SocietyCancer Facts &
Figures 2014. Atlanta: American Cancer Society; 2014
|
|
2
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer: Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deng GL, Zeng S and Shen H: Chemotherapy
and target therapy for hepatocellular carcinoma: New advances and
challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petraccia L, Onori P, Sferra R, Lucchetta
MC, Liberati G, Grassi M and Gaudio E: MDR (multidrug resistance)
in hepatocarcinoma clinical-therapeutic implications. Clin Ter.
154:325–335. 2003.(In Italian). PubMed/NCBI
|
|
5
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohtsu A: Chemotherapy for metastatic
gastric cancer: Past, present, and future. J Gastroenterol.
43:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Obert E, Strauss R, Brandon C, Grek C,
Ghatnekar G, Gourdie R and Rohrer B: Targeting the tight junction
protein, zonula occludens-1, with the connexin43 mimetic peptide,
aCT1, reduces VEGF-dependent RPE pathophysiology. J Mol Med (Berl).
95:535–552. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsuoka H, Shima A, Uda A, Ezaki H and
Michihara A: The retinoic acid receptor-related orphan receptor a
positively regulates tight junction protein claudin
domain-containing 1 mRNA expression in human brain endothelial
cells. J Biochem. 161:441–450. 2017.PubMed/NCBI
|
|
9
|
Liu W, Mi S, Ruan Z, Li J, Shu X, Yao K,
Jiang M and Deng Z: Dietary tryptophan enhanced the expression of
tight junction protein ZO-1 in intestine. J Food Sci. 82:562–567.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Morita K, Furuse M, Fujimoto K and Tsukita
S: Claudin multigene family encoding four-transmembrane domain
protein components of tight junction strands. Proc Natl Acad Sci
USA. 96:511–516. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furuse M, Fujita K, Hiiragi T, Fujimoto K
and Tsukita S: Claudin-1 and-2: Novel integral membrane proteins
localizing at tight junctions with no sequence similarity to
occludin. J Cell Biol. 141:1539–1550. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim B and Breton S: The MAPK/ERK-signaling
pathway regulates the expression and distribution of tight junction
proteins in the mouse proximal epididymis. Biol Reprod. 94:222016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akizuki R, Shimobaba S, Matsunaga T, Endo
S and Ikari A: Claudin-5, −7 and −18 suppress proliferation
mediated by inhibition of phosphorylation of Akt in human lung
squamous cell carcinoma. Biochim Biophys Acta. 1864:293–302. 2017.
View Article : Google Scholar
|
|
14
|
Yang Y, Cheon S, Jung MK, Song SB, Kim D,
Kim HJ, Park H, Bang SI and Cho D: Interleukin-18 enhances breast
cancer cell migration via down-regulation of claudin-12 and
induction of the p38 MAPK pathway. Biochem Biophys Res Commun.
459:379–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang WN, Li W, Wang XL, Hu Z, Zhu D, Ding
WC, Liu D, Li KZ, Ma D and Wang H: CLDN1 expression in cervical
cancer cells is related to tumor invasion and metastasis.
Oncotarget. 7:87449–87461. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuo KT, Chen CL, Chou TY, Yeh CT, Lee WH
and Wang LS: Nm23H1 mediates tumor invasion in esophageal squamous
cell carcinoma by regulation of CLDN1 through the AKT signaling.
Oncogenesis. 5:e2392016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kominsky SL: Claudins: Emerging targets
for cancer therapy. Expert Rev Mol Med. 8:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moldvay J, Fábián K, Jäckel M, Németh Z,
Bogos K, Furák J, Tiszlavicz L, Fillinger J, Döme B and Schaff Z:
Claudin-1 protein expression is a good prognostic factor in
non-small cell lung cancer, but only in squamous cell carcinoma
cases. Pathol Oncol Res. 23:151–56. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun BS, Yao YQ, Pei BX, Zhang ZF and Wang
CL: Claudin-1 correlates with poor prognosis in lung
adenocarcinoma. Thorac Cancer. 7:556–563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vu NB, Nguyen TT, Tran LC, Do CD, Nguyen
BH, Phan NK and Pham PV: Doxorubicin and 5-fluorouracil resistant
hepatic cancer cells demonstrate stem-like properties.
Cytotechnology. 65:491–503. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tolba MF and Abdel-Rahman SZ:
Pterostilbine, an active component of blueberries, sensitizes colon
cancer cells to 5-fluorouracil cytotoxicity. Sci Rep. 5:152392015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nakagawa S, Miyoshi N, Ishii H, Mimori K,
Tanaka F, Sekimoto M, Doki Y and Mori M: Expression of CLDN1 in
colorectal cancer: A novel marker for prognosis. Int J Oncol.
39:791–967. 2011.PubMed/NCBI
|
|
25
|
Jian Y, Chen C, Li B and Tian X:
Delocalized Claudin-1 promotes metastasis of human osteosarcoma
cells. Biochem Biophys Res Commun. 466:356–361. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao X, Zou Y, Gu Q, Zhao G, Gray H,
Pfeffer LM and Yue J: Lentiviral vector mediated Claudin1 silencing
inhibits epithelial to mesenchymal transition in breast cancer
cells. Viruses. 7:2965–2979. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fortier AM, Asselin E and Cadrin M:
Keratin 8 and 18 loss in epithelial cancer cells increases
collective cell migration and cisplatin sensitivity through
claudin1 up-regulation. J Biol Chem. 288:11555–7129. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JW, Hsiao WT, Chen HY, Hsu LP, Chen
PR, Lin MD, Chiu SJ, Shih WL and Hsu YC: Upregulated claudin-1
expression confers resistance to cell death of nasopharyngeal
carcinoma cells. Int J Cancer. 126:1353–1366. 2010.PubMed/NCBI
|
|
29
|
Kim H, Kim Y and Jeoung D: DDX53 promotes
cancer stem cell-like properties and autophagy. Mol Cells.
40:54–65. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee YJ and Jang BK: The role of autophagy
in hepatocellular carcinoma. Int J Mol Sci. 16:26629–26643. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jang JE, Eom JI, Jeung HK, Cheong JW, Lee
JY, Kim JS and Min YH: Targeting AMPK-ULK1-mediated autophagy for
combating BET inhibitor resistance in acute myeloid leukemia stem
cells. Autophagy. 13:761–762. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nie T, Yang S, Ma H, Zhang L, Lu F, Tao K,
Wang R, Yang R, Huang L, Mao Z and Yang Q: Regulation of ER
stress-induced autophagy by GSK3b-TIP60-ULK1 pathway. Cell Death
Dis. 7:e25632016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim J, Kundu M, Viollet B and Guan KL:
AMPK and mTOR regulate autophagy through direct phosphorylation of
Ulk1. Nat Cell Biol. 13:132–141. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mercer CA, Kaliappan A and Dennis PB: A
novel, human Atg13 binding protein, Atg101, interacts with ULK1 and
is essential for macroautophagy. Autophagy. 5:649–662. 2009.
View Article : Google Scholar : PubMed/NCBI
|
